EUR 1.6 million to finish a sizeable EUR 16 million Series A: long-time alumnus
@EBA_Med closes its financing round. Congratulations to the TOP 100 Swiss scale-up shaping the future of medicine with non-invasive and automated treatments of heart arrhythmias!
venturekick.ch/EBAMed-secure…
The funding is provided by CDP Venture Capital SGR under the PNRR (Piano Nazionale di Ripresa e Resilienza) and the Next Generation EU initiative.
Specializing in a guidance system for non-invasive heart arrhythmia treatment using Proton Therapy, EBAMed had initially secured EUR 14.35 million in June 2023.
EBAMed participated in Venture Leaders Life Sciences 2018, won Venture Kick stage 3 in 2018, and was ranked in the TOP 100 Swiss Startup Award in 2019, 2022, and 2023.
#VentureKick #SwissStartups